Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors

Fig. 3

Exposure duration and overall response. Abbreviations: SD, stable disease. PD, progressive disease. ACC, adenoid cystic carcinoma. BC, breast cancer. BTC, biliary tract cancer. CRC, colorectal cancer. DA, duodenal adenocarcinoma. EC, endometrial carcinoma. GEJC, gastroesophageal junction carcinoma. MCLN, metastatic carcinoma of lymph nodes. MPM, malignant pleural mesothelioma. NSCLC, non-small cell lung cancer. NPC, nasopharyngeal carcinoma. OC, ovarian cancer. PA, pancreatic adenocarcinoma. PP, pelvic paraganglioma. RPC, renal pelvis carcinoma. SCLC, small cell lung cancer. TC, thyroid carcinoma. THYM, thymic carcinoma. UC, urachus carcinoma. US, uterus sarcoma

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us